کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10158294 | 1666522 | 2018 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
IlaprazoleTBILPPIsTDMHLMVRCALTALBNADPHDDIsCyPESOOMEiLA - ILAAST - آسپارتات ترانس آمینازAspartate aminotransferase - آسپارتات ترانس آمیناز یا AST Alanine aminotransferase - آلانین آمینوترانسفرازAlbumin - آلبومینOmeprazole - امپرازولstandard deviation - انحراف معیارInhibition - بازداریdrug-drug interactions - تعاملات داروییCytochrome P450 - سیتوکروم پی۴۵۰Pharmacokinetics - فارماکوکینتیکLAn - لنLansoprazole - لنزوپرازولPAN - ماهی تابهProton pump inhibitors - مهار کننده های پمپ پروتونHuman Liver Microsomes - میکروسومهای کبدی انسانیtherapeutic drug monitoring - نظارت بر دارودرمانیnicotinamide adenine dinucleotide phosphate - نیکوتین آمید adenine dinucleotide phosphatevoriconazole - وریکونازولPantoprazole - پانوترازولtotal bilirubin - کل بیلی روبین
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Voriconazole (VRC) and proton pump inhibitors (PPIs) have similar metabolic pathways. The objectives of the study are to evaluate the impact of PPIs on the pharmacokinetics of VRC. Human liver microsomes model was applied to assess the inhibitory effects of PPIs on the metabolism of VRC in vitro. A retrospective study was also carried out to explore the relationship between the plasma VRC trough concentrations and PPIs uses. Patients were divided into six groups: control (nâ=â166), lansoprazole (LAN, nâ=â38), esomeprazole (ESO, nâ=â19), omeprazole (OME, nâ=â45), pantoprazole (PAN, nâ=â43), and ilaprazole (ILA, nâ=â38) groups. All five PPIs showed concentration-dependent inhibitory effects on the VRC metabolism in human liver microsomes, among which LAN, OME and ESO were three of the most potent inhibitors. Consistently, co-administered with LAN, OME and ESO significantly increased the plasma VRC trough levels (pâ<â 0.05), whereas there was no significant association between VRC concentrations and PAN or ILA use. Interestingly, patients in the PPIs groups were more likely to reach the therapeutic VRC range of 1-5.5 μg/mL in steady state when compared with control patients (75-81% VS 69%). In conclusion, although all PPIs showed inhibitory effects on the VRC metabolism in vitro, only LAN, OME and ESO significantly increased VRC plasma concentrations. This study should be helpful for choice of the type of PPIs for patients administered with VRC.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biomedicine & Pharmacotherapy - Volume 108, December 2018, Pages 60-64
Journal: Biomedicine & Pharmacotherapy - Volume 108, December 2018, Pages 60-64
نویسندگان
Miao Yan, Zhu-feng Wu, Dan Tang, Feng Wang, Yi-wen Xiao, Ping Xu, Bi-kui Zhang, Yi-ping Liu, Da-xiong Xiang, Hoan Linh Banh,